Wei, Changli http://orcid.org/0000-0001-8876-8871
Datta, Prasun K.
Siegerist, Florian http://orcid.org/0000-0003-1629-4982
Li, Jing
Yashwanth, Sudhini
Koh, Kwi Hye http://orcid.org/0000-0002-8210-6110
Kriho, Nicholas W.
Ismail, Anis
Luo, Shengyuan
Fischer, Tracy http://orcid.org/0000-0003-4859-3776
Amber, Kyle T.
Cimbaluk, David
Landay, Alan
Endlich, Nicole
Rappaport, Jay
Vasbinder, Alexi
Anderson, Elizabeth
Catalan, Tonimarie
Pizzo, Ian
Bitterman, Brayden
Erne, Grace
Machado-Diaz, Kristen
Presswalla, Feriel
Nelapudi, Namratha
Amadi, Kingsley-Michael
Bardwell, Alina
Blakely, Pennelope
Huang, Yiyuan
Banerjee, Mousumi
Pop-Busui, Rodica
Hayek, Salim S. http://orcid.org/0000-0003-0180-349X
Reiser, Jochen http://orcid.org/0000-0002-0460-662X
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P51OD011104)
Article History
Received: 8 March 2023
Accepted: 14 July 2023
First Online: 21 July 2023
Competing interests
: J. Reiser is co-founder and shareholder of Walden Biosciences, a biotechnology company that develops novel kidney protective therapies. The remaining authors declare no competing interests.